Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-P Armand

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Cancer|January 15, 1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesisG Schwartsmann, E Bork, J B Vermorken, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersJ C Soria, C Massard, N Magné, et al.
British Journal of Cancer|October 3, 1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neckC Couteau, N Chouaki, S Leyvraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I studyG G Chabot, J P Armand, C Terret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinomaS Faivre, T Le Chevalier, C Monnerat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group studyJ H Schornagel, J Verweij, P H de Mulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2000
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinomaP Rougier, A Adenis, M Ducreux, et al.
British Journal of Clinical Pharmacology|November 26, 2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)Charlotte van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Cancer|January 15, 1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesisG Schwartsmann, E Bork, J B Vermorken, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersJ C Soria, C Massard, N Magné, et al.
British Journal of Cancer|October 3, 1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neckC Couteau, N Chouaki, S Leyvraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I studyG G Chabot, J P Armand, C Terret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinomaS Faivre, T Le Chevalier, C Monnerat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group studyJ H Schornagel, J Verweij, P H de Mulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2000
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinomaP Rougier, A Adenis, M Ducreux, et al.
British Journal of Clinical Pharmacology|November 26, 2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)Charlotte van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 15